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orldwide, an estimated 37 million people are living with HIV infection, and more than 2 million new infections are diagnosed annually. 1 HIV-positive individuals are at increased risk for both acute and chronic kidney disease (CKD). The classic kidney disease of HIV infection, HIV-associated nephropathy (HIVAN), has become less common with widespread use of antiretroviral therapy (ART); however, there has been a simultaneous increase in the prevalence of other kidney diseases. HIV-positive individuals are also exposed to lifelong ART, with the potential to cause or exacerbate kidney injury. Newer guidelines recommending earlier initiation of ART may further reduce the incidence of HIVAN, but the overall risk-benefit for kidney health is unknown.
Clinical guidelines for CKD prevention and treatment in HIV-positive individuals are extrapolated from studies in the general population, 2 and current therapies do not target unique HIV-related pathways and genetic factors that contribute to CKD progression. In March 2017, Kidney Disease: Improving Global Outcomes (KDIGO) convened a multidisciplinary, international panel of clinical and scientific experts to identify and discuss key issues relevant to the optimal diagnosis and management of kidney disease in HIVpositive individuals. The primary goals were to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of ART; and define best practices to delay the progression of kidney disease and to treat end-stage kidney disease (ESKD) in HIV-positive individuals.
Renal pathology in the setting of HIV infection
The spectrum of renal pathology in HIV-positive individuals is diverse, including lesions directly related to intrarenal HIV gene expression and lesions related to comorbidities, drug effects, immune dysregulation, and co-infections. 3 Kidney biopsy is required to distinguish between these lesions. A useful approach to classification is based on the major tissue compartment affected (Table 1) . A brief description of each histologic lesion is provided below, and more comprehensive descriptions are available in the Supplementary Appendix.
Glomerular-dominant diseases:
podocytopathy. Glomerular-dominant diseases include 2 main subcategories: podocytopathies and immune complex-mediated.
Four major subtypes of podocytopathy are seen in the setting of HIV: classic HIVAN, focal segmental glomerulosclerosis (FSGS) not otherwise specified (NOS), and rarer cases of minimal change disease and diffuse mesangial hypercellularity. 4 All exhibit extensive podocyte foot process effacement and proteinuria, with absent or minimal immune complex deposition. There is a well-established causal relationship between HIVAN and HIV infection, mediated by direct HIV infection of renal epithelial cells, intrarenal viral gene expression, and dysregulation of host genes governing cell differentiation and cell cycle. 5 The role of genetic susceptibility in the pathogenesis of HIVAN and other podocytopathies is discussed in detail in the next section.
We recommend distinguishing classic HIVAN from FSGS (NOS) in the setting of HIV infection. Direct causality of HIV can only be established with reasonable certainty in classic HIVAN and congenital cases of podocytopathy in infants born to HIV-positive mothers. We recommend that the biopsy report should indicate the degree of certainty that the pathology is causally related to HIV infection as high, moderate, or low.
Classic HIVAN. Classic HIVAN is defined as collapsing glomerulopathy and attendant tubulointerstitial disease, including tubular microcyst formation, interstitial inflammation, and tubular injury ( Figure 1) . 6, 7 Glomerular "collapse" is defined as at least 1 glomerulus with collapse of glomerular basement membranes accompanied by hypertrophy and hyperplasia of the overlying glomerular epithelial cells. These hyperplastic cells may fill the urinary space, forming pseudocrescents. 8, 9 By electron microscopy, diffuse podocyte foot process effacement and endothelial tubuloreticular inclusions (interferon footprints) are classic features. 6, 7 By immunofluorescence, there may be staining for IgM, C3, and C1q in collapsed segments and mesangial areas. 7 Protein resorption droplets may stain for albumin and Ig. In late stages, the sclerotic tuft is retracted into a tight solid sphere, capped by a monolayer of cobblestone epithelium; this has been described as resembling a "fetal glomerulus." 10 Phenotypic studies suggest that the glomerular epithelial cell monolayer is composed of parietal epithelial cells. 8 In some cases, sequential biopsy and postmortem studies have shown 
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an evolution from collapsing glomerulopathy to FSGS (NOS). 7 Tubulointerstitial disease is an invariable component of HIVAN and often appears out of proportion to the glomerular disease, 6, 7 causing kidney enlargement and hyperechoic appearance by ultrasound. Tubular microcysts are dilated tubules (at least 3-fold larger than normal) containing glassy proteinaceous casts and lined by simplified epithelium. Tubular microcysts are easily distinguished from tubular thyroidization based on their larger diameter, irregular size, and the absence of tubular atrophy or colloid-type casts.
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The microcysts may involve all tubular segments, and intracellular viral transcript expression has been demonstrated. 12 Prominent interstitial inflammation 7 and tubular degenerative and regenerative changes may also occur. 13 Interstitial edema in the acute phase is followed by fibrosis and tubular atrophy.
FSGS (NOS) in the setting of HIV. In ART-treated patients, noncollapsing FSGS (NOS) is more commonly encountered at biopsy. 9, [14] [15] [16] Causality is presumed when no other etiology for FSGS can be identified. Viral load is often undetectable, and biopsy findings may be difficult to distinguish from arterionephrosclerosis of hypertension, aging, and APOL1-associated nephropathy. Such cases typically lack prominent tubulointerstitial disease, and the degree of podocyte effacement is generally less severe than in HIVAN (Figure 1 ). These differences have been hypothesized to reflect attenuation of the renal phenotype by ART. 9 Podocytopathy in perinatal HIV infection. In addition to classic HIVAN, children with perinatal HIV infection can present with minimal change disease or diffuse mesangial hypercellularity with numerous endothelial tubuloreticular inclusions and marked foot process effacement. 17 Tubular microcysts and interstitial inflammation are often lacking. Such cases are rare in the ART era.
Glomerular-dominant diseases: immune complex kidney disease in the setting of HIV. Numerous forms of immune complex-mediated glomerular disease have been reported in HIV-positive individuals. 18 We recommend that the commonly used term "HIV immune complex kidney disease" (HIVICK) be replaced with a specific description of the pattern of immune complex disease "in the setting of HIV." The rationale for this approach is the heterogeneous spectrum of disease and the lack of certainty of HIV causality in most cases. Early studies that eluted glomerular immune deposits and demonstrated immune complexes containing HIV antigen and specific anti-HIV antibody were performed on a small number of well-characterized cases in the research setting and are not practicable in routine pathology laboratories. 19, 20 Reflex diagnosis as HIVICK may preclude workup for other secondary, treatable causes.
A unique lupus-like nephritis with full-house immune staining but negative serologies and no clinical signs of systemic lupus erythematosus has been reported in HIV-positive individuals; 21 true lupus nephritis also occurs. 22 It remains unclear whether IgA nephropathy in the setting of HIV is coincidental and related to undergalactosylated IgA1 or due to deposition of IgA directed to viral antigen, as demonstrated in a well-characterized case. 19 An unusual ultrastructural appearance of subepithelial deposits, or "ball in cup" lesion, has been described in reports from South Africa, 10, 23 but is rarely observed in other settings. Other secondary causes should be sought in cases of membranous nephropathy (i.e., hepatitis B virus co-infection or anti-PLA2R autoantibodies) and membranoproliferative glomerulonephritis (hepatitis C virus co-infection). [24] [25] [26] Tubulointerstitial disease in the setting of HIV. As described above, classic HIVAN is a pan-nephropathy with an important tubulointerstitial component; 6, 7 in biopsies with undersampled glomeruli, the characteristic glomerular lesions may not be demonstrable. Acute tubular necrosis may occur in association with sepsis, volume depletion, and other ischemic or toxic insults. 4 The commonly used antiretroviral agent tenofovir disoproxil fumarate can cause proximal tubulopathy with characteristic dysmorphic mitochrondria (Figure 2 ). 27 Tubulointerstitial nephritis can occur secondary to antibiotics, proton pump inhibitors, nonsteroidal antiinflammatory drugs, protease inhibitors, and other medications, as well as in response to mycobacterial infection. [28] [29] [30] Direct infection of the renal parenchyma by other pathogens can also occur. hyperimmune reaction against HIV that involves the kidneys in approximately 10% of cases. [31] [32] [33] Immune reconstitution inflammatory syndrome is an inflammatory disorder associated with paradoxical unmasking or worsening of preexisting infectious processes after ART initiation, 34 rarely involving the kidney. Both conditions are characterized by prominent CD8 T-cell infiltrates.
Vascular-dominant diseases in the setting of HIV.
Thrombotic microangiopathy was reported in the early years of the AIDS epidemic, but is rare in the ART era. 35 A role for direct endothelial dysregulation by HIV has been proposed. 36 Other pathologies in the setting of HIV. As patients with HIV infection age, comorbid kidney diseases such as diabetic nephropathy and arterionephrosclerosis are increasingly common. When secondary FSGS develops in these contexts, the potential overlap with HIV-related podocytopathy can be diagnostically challenging. Molecular approaches demonstrating renal epithelial cell infection by HIV have been used in the research setting for decades, but have not been incorporated into routine diagnostic practice. 37 In addition to these established approaches, several novel and emerging techniques could be incorporated into research and diagnostic renal pathology to better characterize the causal relationship between HIV and specific histologic lesions and to further delineate the host pathways involved. The conference attendees identified several particularly relevant techniques (Supplementary Table S1 ).
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Genetics/genomics of kidney disease in the setting of HIV infection Classic HIVAN occurs predominantly in individuals of African ancestry, with 18-to 50-fold increased prevalence. 40 Two studies involving mapping by admixture linkage disequilibrium published in 2008 identified a region on chromosome 22 strongly associated with idiopathic FSGS and HIVAN in African Americans; 41, 42 however, finemapping revealed no coding variants to explain the association of intronic single-nucleotide polymorphisms in the candidate gene MYH9 with kidney disease. 43, 44 Subsequently, using data from the 1000 Genomes Project, Genovese et al. identified 2 missense variants (G1 allele) and a 6 bp deletion (G2 allele) in the adjacent APOL1 gene that were recessively associated with FSGS and nondiabetic ESKD.
45 APOL1 encodes apolipoprotein L1, which confers innate immunity against most strains of Trypanosoma brucei;
46,47 G2 variants extend immunity to T.b. rhodesiense and G1 associates with asymptomatic carriage of T.b. gambiense, the causes of acute and chronic African human trypanosomiasis, respectively. 45, 48 Coding variants in APOL1 are present only on African-ancestry haplotypes. 49, 50 APOL1 was strongly associated with FSGS (odds ratio [OR] 17) and HIVAN (OR 29) in African Americans and with HIVAN in South Africans (OR 89). 49, 51 In contrast, HIVpositive Ethiopians, who lack APOL1 risk variants, do not develop HIVAN. 52 Subsequent studies have confirmed the strong association between the high-risk genotypes and the diagnosis of HIVAN ( Table 2 ). The estimated lifetime risk associated with carrying 2 APOL1 risk alleles is 4% for FSGS in the absence of HIV infection, and as high as 50% for HIVAN (Supplementary Table S2) . 53 Despite the strong association, w20% to 30% of African Americans with HIVAN have 0 or 1 APOL1 risk allele, suggesting that other genetic, viral, or environmental factors contribute to HIVAN. HIV-positive children with CKD and high-risk genotypes have lower eGFR and experience more rapid progression 58, 153 Multiple mechanisms have been proposed for APOL1-mediated podocyte injury, but they converge in perturbations of endosomal trafficking, increased membrane permeability, and cytotoxicity 61, [63] [64] [65] APOL1, a component of the innate immune system, is up-regulated by interferons 61, 62 High levels of APOL1 may be a "second hit" and sufficient to cause kidney disease 61, 62 APOL1, apolipoprotein L1; ART, antiretroviral therapy; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; FSGS (NOS), focal segmental glomerulosclerosis, not otherwise specified; HIVAN, HIV-associated nephropathy; MYH9, myosin heavy chain 9 gene. Characteristics of APOL1-mediated kidney disease are summarized in Table 3 . The distribution of the APOL1 coding variants varies greatly among sub-Saharan African populations, with the highest frequencies reported in Western Africa (>40% for G1) and much lower frequencies elsewhere in Africa (Supplementary Figure S1) . 50, 52, 55 As a consequence of the West African diaspora in the Americas and more recent African emigrations, APOL1 variants are widely dispersed globally (e.g., 21% and 13% for G1 and G2, respectively, in African Americans). 45, 50 Prediction of histology. Given the strong genetic association, investigators in the United States (US) evaluated whether APOL1 genotype could be used to predict HIVAN or FSGS (NOS) histology in HIV-positive patients of African descent. 56 Inclusion of the high-risk genotype did not significantly add to a predictive model including CD4þ cell count and HIV-RNA, suggesting that APOL1 genotype cannot replace kidney biopsy for definitive diagnosis of HIVAN.
Carriage of APOL1 high-risk genotypes in HIV-positive individuals is not associated with immune complex kidney disease ( Table 2 ). In a US series, high-risk genotypes were present in only 3% of patients with biopsy-proven immune complex disease. 57 Similarly, in a South African series, highrisk genotypes were present in 79% of HIVAN cases but in only 25% of those with HIV and immune complex kidney disease. 51 Renal survival and ESKD risk. In general population studies, the high-risk APOL1 genotypes have been associated with increased risk of CKD progression and with lower estimated glomerular filtration rate (eGFR). 58 In children with perinatal HIV infection, those with a high-risk genotype had 3-fold increased odds of CKD and presented at a younger median age compared with those with 0 or 1 risk allele. 51 In HIV-positive adults with non-HIVAN kidney disease on biopsy, carriage of 2 APOL1 risk alleles was associated with more rapid progression and a 2-fold greater risk of ESKD. 57 Carriage of 2 APOL1 risk alleles has been associated with proteinuria in HIV-infected women and with accelerated decline in longitudinal kidney function in unsuppressed HIVinfected men.
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Mechanisms of APOL1-mediated disease. Two APOL1 risk alleles are required to confer increased risk of kidney disease. However, the presence of high-risk genotypes in healthy populations suggests that disease expression requires a "second hit," such as infections (e.g., HIV or viral hepatitis), interferon, gene-gene interactions, illicit drug use, and other CKD risk factors.
The mechanism of APOL1-mediated kidney disease is currently unknown. Evidence from in vitro experiments in human cells and APOL1 transgenic mouse models suggests that interferon upregulates APOL1 expression, causing podocyte injury. 61, 62 Intracellular apolipoprotein L1 in renal epithelium may cause apoptosis or autophagy by increasing cellular and mitochondrial membrane permeability. [63] [64] [65] In cell culture, G1 and G2 APOL1 variants induce intracellular loss of potassium, cell swelling, and cell lysis. 66 Studies in yeast, Drosophila, and human cells indicate that variant apolipoprotein L1 depolarizes cell membranes, which disrupts intracellular processes including endosomal trafficking, vesicle acidification, and mitochondrial function. [63] [64] [65] In vivo, the expression of high-risk APOL1 variants in transgenic mouse models has produced variable effects. In a model with inducible APOL1 expression, high-risk variants disrupted endosomal trafficking and vesicle acidification, similar to the effects observed in vitro. Affected animals developed podocyte death, proteinuria, and glomerulosclerosis. 61 However, another transgenic mouse model with constitutive expression of APOL1-G2 did not develop kidney disease.
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APOL1 is encoded in the genome of only a few primate species, complicating the extrapolation of data from murine models. Mechanistic studies have also been limited by the use of overexpression assays. In vitro, the overexpression of wildtype APOL1-G0 in cultured human renal epithelial cells also induces cell death, suggesting that the overexpression model may not be biologically relevant. 62, 68, 69 Antiretroviral therapy (ART) nephrotoxicity HIV treatment guidelines recommend immediate initiation of ART in all HIV-positive individuals. Immuno-virological control is an important strategy to reduce the incidence of acute kidney injury (AKI) and HIV-related kidney diseases. [70] [71] [72] [73] The presence of CKD affects the choice and dosing of renally cleared antiretrovirals. Kidney function and CKD risk factors should be assessed prior to ART initiation (Figure 3) . CKD risk scores have been developed to guide clinicians, although future studies are needed to determine their utility in diverse populations (Supplementary Table S3 ). 74, 75 The widely used antiretroviral agent tenofovir disoproxil fumarate (TDF) is generally safe and well tolerated, but has important potential for cumulative nephrotoxicity. Subclinical proximal tubular dysfunction (low-level proteinuria and excessive phosphaturia) is common, and approximately 1% to 2% of recipients develop treatment-limiting tubulopathy. 76 Risk factors for tubulopathy include aging, immunodeficiency, diabetes, prolonged exposure, and concomitant use of didanosine or ritonavir-boosted protease inhibitors. 77 Severe tubulopathy may progress to eGFR decline, osteomalacia, and pathological fractures. In large observational studies, TDF has also been associated with decreased eGFR or creatinine clearance, 78, 79 as well as with rapid eGFR decline and proteinuria. 78, 79 Co-administration of TDF with ritonavir-boosted protease inhibitors increases the risk. 78, 79 Although not well studied, the newer pharmacoenhancer cobicistat also increases tenofovir exposure and may increase the risk of toxicity. TDF discontinuation and switches from TDF to the newer prodrug tenofovir alafenamide (TAF) have been associated with improved kidney function, although the long-term safety of TAF is not known.
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Any drug (antiretroviral or other) may cause interstitial nephritis. New-onset eGFR decline or proteinuria should prompt careful review of CKD risk factors and medications. 29, 84 Among antiretrovirals, atazanavir and indinavir have been most commonly linked to interstitial nephritis and nephrolithiasis; other protease inhibitors have been implicated in case reports. [85] [86] [87] [88] [89] Observational cohort studies have also linked atazanavir and lopinavir/ritonavir to rapid eGFR decline and incident CKD, 78, 79 and switching from ritonavir-boosted atazanavir or lopinavir to boosted darunavir has been associated with improved kidney function. 90 In settings where TAF, abacavir, and darunavir are available, the use of TDF, atazanavir, and lopinavir/ritonavir should ideally be avoided in those with CKD, rapid eGFR decline (>3-5 ml/min per 1.73 m 2 per year), or at high CKD risk. The threshold for avoiding or discontinuing these agents may be influenced by local circumstances. In resource-limited settings, TDF dose adaptation may be an option. Dual therapy (i.e., boosted protease inhibitor plus lamivudine or raltegravir) has been proposed as a way to avoid concomitant use of boosted protease inhibitors with TDF, thereby minimizing the nephrotoxic potential. [91] [92] [93] Pharmacological considerations. Several antiretrovirals require dose adjustment in individuals with decreased eGFR (Supplementary Table S4 ). If continued use of TDF is required when eGFR is <60 ml/min per 1.73 m 2 (or <70 ml/ min per 1.73 m 2 with eGFR decline), dose adjustment should be considered.
Drug-drug interactions are common with ART. Several antiretrovirals induce or inhibit absorption (through Pglycoprotein), hepatic metabolism (through the cytochrome P450 system or glucuronidation), and/or tubular excretion (through organic anion and cation transporters, and multidrug resistant or multidrug and toxin extrusion proteins) of co-administered medications. We recommend that clinicians consult available resources such as www.hiv-druginteractions. org.
CKD progression and ESKD in the setting of HIV infection
Risk factors for CKD. Both HIV-related and traditional CKD risk factors influence CKD development and progression ( Figure 4 ). With improved longevity among HIV-positive individuals, traditional CKD risk factors, particularly hypertension and diabetes, are of increasing concern worldwide. [94] [95] [96] Hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infections are associated with a 2-to 3-fold increased risk of progressive CKD. 97, 98 Other co-infections such as tuberculosis and syphilis may also contribute to CKD risk. [99] [100] [101] In addition, severe AKI has been associated with a 3.8-to 20-fold increased risk of progression to ESKD. 102 CKD screening and monitoring. Studies to inform the optimal CKD screening and monitoring strategies among HIV-positive individuals are lacking. Until such studies exist, current CKD guidelines should be followed. Serum creatinine is the preferred biomarker for estimating GFR. 2, 103 Serum cystatin C may be considered in patients receiving medications that alter tubular creatinine handling. Cystatin C may also better predict long-term mortality, 104, 105 but is susceptible to bias in the setting of inflammation. The serum creatinine-based CKD-EPI equation is generally preferred; 2,103 however, none of the available estimates have been validated in diverse populations or in the setting of drugs that alter creatinine secretion. [106] [107] [108] Use of the antiretrovirals dolutegravir or rilpivirine or the pharmacoenhancers ritonavir or cobicistat may result in average reductions in calculated creatinine clearance of around 5 to 20 ml/min, which should be taken into account when interpreting eGFR or creatinine clearance. 109 Clinicians should also be aware that serum creatinine measurements may not be standardized in resource-limited regions and that extrarenal factors may alter both serum creatinine and cystatin C concentrations (Supplementary Table S5 ). [110] [111] [112] Rather than a single eGFR value, eGFR trajectories are useful for identifying individuals with progressive decline in kidney function.
Urinalysis should be performed in all HIV-positive individuals to detect worsening or new onset of proteinuria or hematuria. Where feasible, quantification of proteinuria (urine albumin-to-creatinine or protein-to-creatinine ratio) should also be performed. In individuals receiving TDF, urinalysis may also detect glycosuria, and plasma phosphate should be monitored if possible. Evaluation of cystatin C, low-molecular weight ("tubular") proteinuria, or phosphate reabsorption is not indicated in individuals with stable kidney function and no indication of TDF toxicity. 113 In most HIV-positive individuals who are stable on ART, annual monitoring of kidney function appears appropriate. In those with or at increased risk of CKD and those who receive TDF with ritonavir-or cobicistat-boosted protease inhibitors, more frequent monitoring is recommended, typically 2-4 times per year depending on risk factors. 113 Kidney function should also be carefully monitored during hospitalization, particularly in individuals receiving TDF and concomitant nephrotoxic medications.
If CKD is identified, patients should undergo work-up based on available resources and risk stratification, including consideration of potential medication toxicity; screening for hypertension, diabetes, and co-infections; and assessment of region-specific risk factors such as traditional medicines. HIVspecific CKD risk scores may facilitate risk-stratification, 74, 75 although these scores have not been validated in diverse populations or in resource-limited settings (Supplementary  Table S3 ). Referral to a nephrologist should be considered in certain settings ( Figure 5) . 103 When the cause of CKD is unclear, CKD progression is rapid, or prognostication is needed, a kidney biopsy should be considered.
CKD management. Evidence from observational studies strongly supports the beneficial effect of early ART initiation on the risk of classic HIVAN. 114 The impact of ART on CKD progression in patients with immune complex kidney diseases is more variable. 71, 72 Given the overwhelming benefit on survival, ART is recommended for all HIV-positive individuals. 115 Evaluation of other treatment strategies for kidney disease in the setting of HIV has been limited to small, single-center studies with short duration, and has focused largely on HIVAN (Supplementary Table S6 
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CR Swanepoel et al.: Kidney disease and HIV: a KDIGO conference report study has evaluated the efficacy of blood pressure control, diabetes treatment, or angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers in slowing CKD progression in HIV-positive individuals. However, extrapolating from the strong evidence supporting the efficacy of these interventions in the general population is reasonable (Table 4) . 103, 116, 117 Treatment of HBV, HCV, and tuberculosis co-infections should be considered based on existing treatment guidelines.
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Kidney replacement therapy (KRT) in HIV-positive individuals. With ART, survival of HIV-positive individuals receiving KRT is comparable to their HIV-negative counterparts. 122 Therefore, HIV serostatus should not influence candidacy for KRT. Observational studies demonstrate similar outcomes between hemodialysis (HD) and peritoneal dialysis (PD) among ART-treated individuals, and modality selection depends upon patient preference and regional resources. 123, 124 Arteriovenous fistulas are the preferred vascular access, as arteriovenous grafts and catheters are associated with higher risk of infection and thrombosis. 125 There is no evidence supporting isolation of HIV-positive patients in HD units, except those with HBV co-infection. 126 Dialyzer reuse by the same patient is practiced in resource-limited settings as a cost-saving alternative. Evidence supporting the safety of dialyzer reuse by HIV-positive individuals is limited, 127, 128 and precautions must be adhered to in order to avoid HIV transmission to other patients and dialysis staff. HIV-positive PD patients may have higher risk of PD catheter infections; however, PD catheter failure rates are similar in HIV-negative patients. 129 PD consumables must be discarded properly, as HIV persists in PD materials and fluid.
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Kidney transplantation in HIV-positive individuals. Kidney transplantation in HIV-positive recipients is associated with Where feasible, quantification of proteinuria (spot urine albumin-to-creatinine or protein-to-creatinine ratio) should also be performed. **More frequent monitoring is recommended in persons who are clinically unstable, severely immunocompromised, or viremic. AKI, acute kidney injury; ART, antiretroviral therapy; CKD, chronic kidney disease; CKD-EPI, CKD Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; TDF, tenofovir disoproxil fumarate.
excellent 1-year and 3-year recipient and allograft survival rates, intermediate to those observed in the overall US kidney transplant population and in a higher risk subgroup of recipients $65 years of age. 132 Registry data also suggest good 5-and 10-year outcomes, with an improvement in survival compared with patients who remain on the wait-list. 133 Studies in other settings have confirmed the safety of kidney transplantation in individuals with well-controlled HIV. 132, [134] [135] [136] [137] [138] Eligible patients with advanced CKD and well-controlled HIV infection should be referred for kidney transplant evaluation (Table 5) .
Immunosuppressant protocols for the general population can be applied to HIV-positive individuals. In view of the increased immunological risk, some centers prefer induction therapy with an interleukin-2 receptor antagonist, polyclonal antithymocyte globulin, or alemtuzumab. 132, 134, 139 Tacrolimus is the calcineurin inhibitor of choice for maintenance immunosuppression. 132, 140 Existing guidelines for prophylaxis against opportunistic infections 141, 142 and management of hepatitis co-infection should be followed. 143, 144 Outcomes for HCV-co-infected recipients are poorer compared with recipients with HIV or HCV mono-infection, but are still superior to those of patients who remain on the wait-list. Clinicians should be aware of significant drug-drug interactions among immunosuppressive agents, ART, and antiviral medications for HCV co-infection. To minimize drug-drug interactions and achieve steady-state drug levels, integrase inhibitors and nucleoside reverse transcriptase inhibitors are the preferred antiretroviral agents, while protease inhibitors and the pharmacoenhancers ritonavir and cobicistat are best avoided. 145 Given the complexity of issues, a multidisciplinary team comprising experts in transplant nephrology, infectious disease, and clinical pharmacology is imperative.
Given the strong association between the APOL1 risk variants and HIVAN, HIV-positive recipients of African descent and those who receive an allograft from a donor of African descent should be monitored for recurrent HIVAN. 146 The relative contribution of donor and recipient APOL1 risk status to the risk of HIVAN recurrence is the subject of ongoing research. The APOL1 Long-term Kidney Transplantation Outcomes (APOLLO) Research Network 147 will investigate the influence of donor APOL1 risk variants on long-term outcomes among recipients and African American donors, including those with HIV.
Based on experience in South Africa, there is growing evidence to support the safety of kidney transplantation from HIV-positive donors. 148, 149 The US HIV Organ Policy Equity (HOPE) Act allows the use of organs from HIV-positive donors in approved research programs. 150, 151 Questions remain about the implications of super-infection in settings where ART resistance is common.
Children and adolescents with HIV
As in adults, CKD screening and monitoring are recommended, and ART should be provided as per international and regional guidelines (Supplementary Table S7 ).
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Conclusion
Despite improved survival with ART, HIV-positive individuals remain at increased risk for kidney disease. This report summarizes recommendations for diagnosis, management, and prevention of kidney disease in this population, including a proposed histologic classification. In the absence of data from randomized controlled trials, these recommendations reflect the expert opinion of conference attendees, incorporating combined clinical experience and evidence from In patients with HCV genotypes 1 and 4 and CKD G4-5, ribavirin-free grazoprevir/elbasvir [156] [157] [158] or glecaprevir/pibrentasvir regimens may be effective 164, 165 In patients with genotypes 2, 3, 5, and 6 and CKD G4-5, the pan-genotypic glecaprevir/pibrentasvir regimen can be used 164, 165 ; sofosbuvir-based regimens can be used in patients with any genotype, but should be avoided or dose adjusted in patients with eGFR < 30 ml/min per 1.73 m 2 . [159] [160] [161] In addition, the combination of ledipasvir and sofosbuvir with TDF should be avoided.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; HCV, hepatitis C; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. *Hemoglobin A1c may underestimate glycemia in HIV-positive individuals. 162, 163 observational studies and laboratory research. A second major outcome of this conference was the identification of knowledge gaps and areas for future research (Table 6) , with the long-term goal of improving the diagnosis and management of kidney disease in HIV-positive individuals.
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